In reply
We agree with Parsons that a niacin/lovastatin combination could be highly cost-effective, provided that patient compliance is high. Clearly, a cost-benefit analysis should be driven by long-term estimates of compliance. Unfortunately, observational data suggest that compliance rates with niacin are lower than that with other lipid-lowering drugs.1